NEW YORK (GenomeWeb) – Myriad Genetics announced late Friday afternoon that 17 new insurance plans have released positive coverage policies for its EndoPredict breast cancer test.

The plans include Blue Shield of California, Humana, and multiple regional plans. Further, Myriad said, Highmark Blue Cross Blue Shield, Independence Blue Cross, and Health Care Service Corporation have posted positive coverage policies which take effect in July 2017. These plans altogether represent more than 35 million covered lives raising the total of lives covered for EndoPredict to 109 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.